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ABSTRACT
This study sought to measure medium-sized extracellular vesicles (mEVs) in plasma, when
patients have low Plasmodium falciparum early in infection. We aimed to define the relationship
between plasma mEVs and: (i) parasitaemia, (ii) period from onset of malaria symptoms until
seeking medical care (patient delay, PD), (iii) age and (iv) gender. In this cross-sectional study,
n = 434 patients were analysed and Nanosight Tracking Analysis (NTA) used to quantify mEVs
(vesicles of 150–500 nm diameter, isolated at 15,000 × g, β-tubulin-positive and staining for
annexin V, but weak or negative for CD81). Overall plasma mEV levels (1.69 × 1010 mEVs mL−1)
were 2.3-fold higher than for uninfected controls (0.51 × 1010 mEVs mL−1). Divided into four age
groups, we found a bimodal distribution with 2.5- and 2.1-fold higher mEVs in infected children
(<11 years old [yo]) (median:2.11 × 1010 mEVs mL−1) and the elderly (>45 yo) (median:1.92 × 1010
mEVs mL−1), respectively, compared to uninfected controls; parasite density varied similarly with
age groups. There was a positive association between mEVs and parasite density (r = 0.587,
p < 0.0001) and mEVs were strongly associated with PD (r = 0.919, p < 0.0001), but gender had no
effect on plasma mEV levels (p = 0.667). Parasite density was also exponentially related to patient
delay. Gender (p = 0.667) had no effect on plasma mEV levels. During periods of low parasitaemia
(PD = 72h), mEVs were 0.93-fold greater than in uninfected controls. As 75% (49/65) of patients
had low parasitaemia levels (20–500 parasites µL−1), close to the detection limits of microscopy of
Giemsa-stained thick blood films (5–150 parasites µL−1), mEV quantification by NTA could
potentially have early diagnostic value, and raises the potential of Pf markers in mEVs as early
diagnostic targets.
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Introduction
The latest WHO World Malaria Report 2018 showed,
for 2017, that there were 435,000 deaths from malaria
[1], the most vulnerable group, under 5 years of age,
accounting for 61% (266,000) of deaths worldwide.
Attempts to eradicate malaria through concerted pro-
grammes of antimalarial drug treatment as well as
vector control have lowered the incidence in Africa
by 17% and mortality by 26%, since 2000 [2,3]. The
Plasmodium parasite however has adapted to these
programmes placing malaria amongst the deadliest dis-
eases [4] with the vast majority of cases and deaths still
particular to Africa [2]. In Ghana, of the 5 species
infecting humans, only three species occur:
P. falciparum, P. ovale and P. malariae [5],
P. falciparum being the most common (90–98% of
infections), followed by P. malariae (2–9% of infec-
tions) and then P. ovale (1%). Although there are
simple interventions that can be adopted to minimize
the impact of the disease, such as proper use of insec-
ticide impregnated nets, prophylaxis and early report-
ing of infection, many of these measures have not
delivered the expected impact [6]. In many commu-
nities, particularly rural ones, the disease may be exa-
cerbated as there is usually a delay in reporting malaria
infection for medical attention after infection [7]. This
may happen for many reasons, amongst which is poor
public health awareness, lack of finance and an over
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reliance on self-medication [8]. Such delays in receiv-
ing proper medical assessment and care, allow the
malaria parasites to rapidly proliferate. This may sti-
mulate the release of Extracellular Vesicles (EVs) from
parasitized erythrocytes as well as other activated cells
[9,10]. These EVs include medium-sized EVs (mEVs)
(also known as microvesicles [MVs]), defined as having
been isolated at 10–20,000 × g [11,12], of 150–500 nm
diameter, and expressing typical medium-sized EV
markers (such as β-tubulin) but negative or with low
expression of small-sized EV markers (CD81) [12,13].
mEVs, expressing a macromolecular profile reminis-
cent of the parent cell [14], are shed from the plasma
membrane either as a result of normal cell physiology
[15] or in increased numbers due to cellular stress or
damage [16], including endoplasmic reticulum stress
and resulting inflammation [17] and during early
apoptosis [18]. Erythrocyte mEVs are released consti-
tutively at basal levels [19] but oxidative stress, ATP
depletion, and calcium ionophore (A23187) may all
stimulate release [20]. Increased levels of mEVs are
also an indicator of infectious disease [21]; mEVs iso-
lated from patients infected with malaria parasites
carry an enriched mixture of host proteins (including
complement proteins) and expressed malaria proteins
[10,22] and their interactions with monocytes and
macrophages usually create a pro-inflammatory
response [23,24]. In view of the roles EVs play in
facilitating infection [25–27] and in particular in the
pathogenesis of cerebral malaria [28], but also in all
stages of cancer progression [29], there has been
a general need to modulate their release. To that end
we and others have recently described a range of phar-
macological agents able to inhibit mEV release from
cells [30–34], including bacteria [35,36].
In mouse infection models using ABCA1 knockouts,
plasma mEV levels rose significantly more in ABCA1+/
+ mice during infection compared to ABCA1−/−, and
these ABCA1 KO mice were protected from cerebral
malaria (CM) [37]. The sequestration of parasitized
cells in blood vessels possibly resulting in CM pointed
to an additional role of mEVs in parasite cytoadher-
ence [38]; similarly Giardia intestinalis mEVs help
mediate attachment of the trophozoites to intestinal
epithelial cells [39]. In falciparum malaria, infected
erythrocytes (iErys) release mEVs that have an
increased expression of phosphatidylserine [40] and
play a role in the cytoadhesion of iErys [41].
Understanding host-parasite interactions, through
the role of mEV-mediated intercellular communica-
tion, as reviewed elsewhere [25,42] will offer opportu-
nities to manage childhood malaria. Recently,
exosome-like vesicles released from malaria-infected
erythrocytes were shown to mediate intercellular com-
munication [10,43], and in other work on host mEVs
in infection, it was shown that T. cruzi metacyclic
trypomastigotes induced mEV release from blood
cells in mice, early in infection [44]. These host mEVs
provided the parasite with protection against activated
host complement attack, resulting in increased parasite
survival in an infection model of T. cruzi in mice. The
release of host-derived mEVs stimulated by intracellu-
lar parasites, which may on the one hand function as
a decoy, may thus also be used opportunistically by
such pathogens to enhance infection [45].
Accurate and early diagnosis of malaria remains an
essential strategy for bringing about early treatment, to
reduce the risk of severe disease, and so prevent further
transmission [7]. Whilst the main diagnostic test for
malaria remains the identification of parasites in blood
films by microscopy, there are alternatives. These
include the rapid diagnostic test that detects antigen
(but lacks sensitivity), serology using ELISA or IFA to
detect previous infection and molecular tests, which are
the most accurate, but also expensive. There is there-
fore still a need to develop technologies with improved
throughput and cost effectiveness, for use in the field
[46]. As the possibility of using EVs in the diagnosis of
various diseases gains traction [47], the prospect of
using plasma EVs as a potential target for diagnosis
of infectious disease is in particular gaining inter-
est [21].
Studies on mEV quantification in plasma have
hitherto been of limited size and not used the latest
technologies. Whilst increased mEV levels have been
shown recently in malaria [9,48,49] two of these studies
were small: n = 36 [9]; n = 37 [49], and a third speci-
fically enumerated circulating endothelial mEVs
(“microparticles”) [48]. To make our large cross-
sectional study more comparable with these earlier
studies we also measured plasma mEV levels, but
used nanosight tracking analysis (NTA) (as opposed
to flow cytometry) for increased accuracy.
In this study carried out over the course of one year
in Ghana, we investigated parasitaemia and corre-
sponding plasma mEV levels that occur when malaria
infection is not reported early enough. Blood samples
of patients were analysed, based on the period from the
onset of symptoms related to malaria (temperature of
≥38°C, vomiting, headaches, muscle pain or diarrhoea)
until seeking medical healthcare, the so-called Patient
Delay (PD) [50–52]. We set out to quantify mEVs in
patients infected with P. falciparum and to ascertain
whether there was any possible influence of parasitae-
mia levels and/or PD as well as age or gender of
patients.
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Materials and methods
Ethics
The protocols for obtaining plasma mEV samples from
patients infected with malaria, and uninfected donor
controls, were approved by the Ethics Committee of
the School of Biomedical and Allied Health Sciences,
Noguchi Memorial Institute for Medical Research,
University of Ghana (NIACUC-2017-02-1Y).
Subjects
The inclusion criteria for uncomplicated malaria
which governed the selection of volunteers for this
study (n = 434, median age 27.3 years; M/F ratio
1.27) included a temperature ≥38°C, P. falciparum-
positive Giemsa-stained blood film and positive
results for P. falciparum (using the Rapid Diagnostic
Test [RDT] described below) as well as negative tests
for other Plasmodium spp. as shown by nested PCR
and microscopy of peripheral blood slides. Gender
and age-matched (±3 years) uninfected controls,
recruited from the healthy community (median age
28.8 years; M/F ratio = 1.005) were also included,
giving a falciparum malaria-infected to uninfected
ratio of 1:1.83. Exclusion criteria for this study
included HIV, bacterial co-infection, diabetes, preg-
nancy, smoking, autoimmune disease, Alzheimer’s
and whether anti-malarials (quinine or artemesinin
combination therapy) had been taken in the previous
6 months. As levels of erythrocyte mEVs are raised in
certain haemoglobinopathies including sickle cell
anaemia (SCA) [53], β-thalassaemia [54] and glu-
cose-6-phosphate dehydrogenase (G6PD) deficiency
[55], these patients were also excluded from the
study. Patients, particularly children and the elderly
showing symptoms or early warnings of severe
malaria [56], or other life-threatening infections were
referred to a health clinic, and also excluded.
The 434 patients, from the Western region of
Ghana, aged between 6 months and 70 years were
incorporated into the study after providing written
consent in accordance with ethical committee guide-
lines from the University of Ghana, College of Health
Sciences, for work on human subjects (see above). For
all cases presenting with mild symptoms of infection
(uncomplicated malaria), as we were unable to report
the exact duration of fever or of clinical symptoms, we
reported the “patient delay,” PD [50–52] or “delay in
seeking healthcare,” defined as the period (≥24 h)
between onset of symptoms (temperature ≥38°C,
vomiting, headaches, muscle pain or diarrhoea) until
seeking medical healthcare. Patients were treated with
antimalarials (a standard course of artemisinin based
derivative combination therapy) and other support
therapies. Venous blood (5 mL) was taken from the
antecubital vein of each patient or donor using a 21-
gauge needle and collected in a 4.5 mL vacutainer (BD
Biosciences) with acid-citrate-dextrose (with gentle
inversion to mix with anticoagulant), having discarded
the first 1 mL. Samples were further processed within
30 min of phlebotomy. To obtain platelet poor plasma
the tubes were spun twice at 2,500 × g for 15 min.
Haemoglobin levels and haematocrit were calculated
using a haematology analyser.
Light microscopy and parasitaemia count
The patients’ blood (5 µL) from a venous blood speci-
men was used to make both a thick and a thin blood
smear. To stain the malaria parasites, the thick films
were stained in 10% Giemsa stain and the thin films
with a Field’s stain. After drying at room temperature,
the slides were examined under a microscope using
a 100× objective lens. Malaria parasites were identified
by their physical features and by the appearance of the
infected erythrocytes.
The number of circulating parasites was ascertained
as follows: Having identified the area of the thick smear
with an even distribution of 10–20 WBC per field,
examination was continued of high power fields, deter-
mining the number of P. falciparum parasites (asexual
blood stage forms) per 200 or 500 WBCs (for lower
parasite densities). Parasite density was calculated as
follows:
ParasiteDensity parasites=μL of whole bloodð Þ
¼ No:of parasites
WBC counted
WBC count=μL
Malaria rapid diagnostic tests (RDTs)
Malaria RDTs were used to test the presence of
P. falciparum and to thus confirm the results of the
microscopy test. All RDTs were equilibrated to room
temperature prior to use. If any colour change was
noted in the desiccant, the RDT was discarded. RDTs
were labelled with patient ID, dilution, and the date
when the test was performed, which was carried out
according to the manufacturer’s instructions.
mEV isolation and flow cytometry (FCM)
Citrate plasma from blood was collected as described
above. In view of the importance of adhering to standard
isolation and characterization protocols [57], such
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procedures were carried out according to the standards
recommended by the International Society for
Extracellular Vesicles (ISEV) [58,59]. To isolate mEVs
as described before [22,32,60] with minor modifications,
2-fold diluted plasma was gently sonicated using
a sonicating water-bath (Townson and Mercer Ltd,
Croydon) for 5 × 1 min, in order to gently disperse any
aggregated exosomes prior to centrifugation at 15,000 × g
for 40min to pellet mEVs, which were then washed in the
same volume of sterilized and filtered (0.22 µm pore size)
phosphate buffered saline (sPBS). For practical reasons,
this washing step was used to reduce levels of lipopro-
teins, protein aggregates and other plasma material [61]
rather than size-exclusion chromatography [62] or den-
sity gradient centrifugation [63]. The supernatant was
discarded and the pellet containing the mEVs re-
suspended in 200 µL of sPBS. Where necessary, mEVs
were frozen at −80°C for shipment on dry ice. The mEV
samples (diluted 1:40 in sPBS) were then quantified using
Nanosight Tracking Analysis (see section on Nanosight
Tracking Analysis). To isolate sEVs, the supernant from
the 15,000 × g above, was centrifuged at 100,000 × g, for
90 min, washed in EV-free sPBS (100,000 × g/90 min)
and resuspended in EV-free sPBS.
Flow cytometry was carried out as described before
[55,64]. Essentially, the mEVs were resuspended in
annexin V (AnV) Binding Buffer (AbCam) and stained
with AnV-FITC (R&D Systems, UK) for detection of
PS on a BD FACSAriaTM flow cytometer utilizing the
1-log more sensitive FSC-PMT (forward scatter photo-
multiplier tube). FlowJo v10.0.7 (Treestar) was used to
analyse the data. As a baseline control, mEVs were
isolated from plasma samples of age- and sex-
matched uninfected donors.
EV size and concentration determination by
nanosight tracking analysis (NTA; nanosightTM)
NTA was carried out as described previously [32,65] to
reveal the size distribution and concentration of iso-
lated mEVs using a NanoSight NS300 (equipped with
a sCMOS camera and 405 nm diode laser; Malvern
scientific). Data were acquired and processed by one
operator throughout the study, using NTA software
version 3.00, based on the minimal information for
studies of EVs (MISEV) [58,59]. With the ambient
temperature taken from the temperature probe and
applied to the software before each reading, settings
for the minimum track length and blur and particle
size were also applied. The NTA was calibrated
each day to ensure consistency between daily readings
using a 100 nm diameter polystyrene bead standard
(Malvern Scientific). Samples were diluted to maintain
20–40 particles per field of view and 6 × 30 s videos
recorded (at camera level 11), the background signal
(from background contamination) being subtracted
before further processing; for analysis, at least 1,000
completed tracks were required per measurement (each
sample being read in triplicate). Absolute number con-
centrations of mEVs were obtained using the following
equation:
plasmaMVs½  ¼ NTA reading
particles
mLð Þdiln:factorsamplevol:
starting plasma vol .
Analyses were always carried out at the same settings
(detection limit 3). The quantification of mEVs is
described throughout in absolute number concentra-
tions of mEVs expressed as the median and modal sizes
± 95% confidence interval (CI), as well as size ranges of
mEVs. NTA analysis was also used to provide the mean
with 95% CI. Fold-change in terms of EV numbers has
been defined throughout as the ratio of the difference
between the final and initial values and the initial value.
Fold-change was converted to % change by multiplying
by 100.
Transmission electron microscopy (TEM)
For TEM, mEVs were stained with 2% aqueous uranyl
acetate, placed on 400-mesh copper Pioloform grids and
pre-treatedwith aqueousAlcian blue 8GX (1%) for 10min.
Using a digital camera, images were recorded on a JEOL
JEM 1200 EX II transmission electron microscope.
Western blotting analysis
mEV lysates, normalized for protein content using the
BCA protein assay (Thermo Fisher) were prepared and
subjected to SDS-PAGE [66]. Reversible zinc staining
(Pierce™ Zinc Stain Kit) was carried out prior to transfer.
After recording the staining as a loading control, the gel
was destained according to the manufacturer’s protocols,
prior to Western blotting, which was carried out as
described before [66]. Samples were probed for expres-
sion of mEV/sEV markers (using β-tubulin/CD81 (both
mouse monoclonal antibodies from Abcam at 1:1,000)).
Throughout, the secondary antibody was goat anti-
mouse HRP conjugate (Bio-Rad; 1:5,000).
Statistical analysis
Statistical analysis was carried out using GraphPad
Prism 6.04 and 8.1.0 (GraphPad Software Inc., La
Jolla, CA). Differences in medians of mEV levels was
analysed using a Wilcoxon signed rank test. P values
(all two-sided) of <0.05 were considered statistically
significant. Correlations between plasma mEVs and
age, parasitaemia and PD were assessed by measuring
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Pearson’s correlation coefficient (r). To model plasma
mEV level dependency with age, procedures to fit
models that are linear and quadratic (second-order
polynomial, which describes a parabola) were
employed; hyperbolic functions were fitted to data for
mEV plasma level variation with parasitaemia. The
statistical significance of the effect of gender on mEV
levels was tested using the Mann–Whitney U-test.
Results
Plasma mEVs are significantly raised in
Plasmodium falciparum infected patients
The clinical data and a summary of the main haema-
tological profile of the patients with falciparum malaria
(median age 27.3 years), in this study that met all the
inclusion criteria as well as that for the uninfected
controls, are presented in Table 1. Over the course of
the study, samples that fell within the exclusion criteria
were not included. Data collected over 1 year, of
patients infected with Plasmodium falciparum was
grouped into those of low parasitaemia (20–50 and
51–500 parasites µL−1), intermediate parasitaemia (-
501–8,000 parasites µL−1) and high parasitaemia (8,-
001–40,000 parasites µL−1). Analysis revealed that 62%
of the 434 patients who suffered a ≥ 4d “patient delay”
(PD) (period from the onset of symptoms to seeking
medical care, also known as period of acute illness [50–
52]) had increased levels of parasitaemia (501–40,000)
(Table 2 and supplementary Figure S1).
mEVs derived from plasma of infected patients in the
range 80–480 nm, based onNTA analysis (Figure 1(a)) and
electron microscopy, compared favourably with other size
estimates from electron microscopy (Figure 1(b)) of
100–400 nm diameter, albeit specifically for erythrocyte
mEVs inmalaria infection [10]. Because of the overlapping
size distribution of sEVs andmEVs, the expression levels of
markers typical of both vesicle sub-types was assessed.
Western blot analysis showed expression of expected mar-
kers for mEVs (β-tubulin, a cytoplasmic marker) but
absent in sEVs isolated from infected pools (12–44 yo);
the sEV tetraspanin marker, CD81 (a plasma membrane
associated protein), was found in sEVs and showed only
weak expression in mEVs (Figure 1(c)). Flow cytometric
analysis of infected patients and uninfected donors, is
shown by representative forward/side scatter plots in
Figure 1(d,e), respectively, and in the plots below, mEVs
were found to stain forAnnexinV (indicating exposition of
phosphatidylserine). This was as expected, certainly for
mEVs released from infected erythrocytes [40].
Overall, we found a significant 2.3-fold (230%)
increase for mEV counts of P. falciparum-infected
patients (median 1.69 × 1010 mEVs mL−1 [95%CI:
1.52–1.83 × 1010 mEVs mL−1]) compared with unin-
fected donors (median 0.514 × 1010 mEVs mL−1 [95%
CI: 0.461–0.563 × 1010 mEVs mL−1]) (age- and sex-
matched controls (p < 0.0001) (Figure 1(f)). Although
there is the possibility in patients with high parasitae-
mia that merozoites (1.5 µm × 1.0 µm [67]) and hae-
mozoin (1 µm long crystals [68]) could be co-purified
with mEVs by centrifugation, the presence of such
material does not affect the accuracy of NTA analysis
[69]. Our estimation of a circulating basal level of
mEVs in uninfected donors (0.514 × 1010 mEVs mL−1
[95%CI: 0.461–0.563 × 1010 mEVs mL−1]) lies within
the range previously described in the blood of unin-
fected individuals, typically 0.17 × 1010–2.4 × 1010
mEVs mL−1 [33,70] and 0.3 × 1010 mEVs mL−1 [71].
Although increased numbers of circulating mEVs have
been identified in individuals presenting with infec-
tious disease [72–74], this has not been accurately
quantified previously for malaria infection.
Elevated levels of plasma mEVs in young and old
patients with low level falciparum malaria
infection
We found no direct relationship (r = 0.033,
p = 0.693) between plasma mEV levels and age
(0.5–70 yo) (Figure 2(a)). However, the curve that
Table 1. Demographic and haematological characteristics of Plasmodium falciparum patients (n = 434).
Patient parameters patients Controls P-value
Age Group Median (range) Median (range)
<11 yo (n = 94) 5.1yo (0.5–8.0) 6.5 yo (0.5–10)
12-25 yo (n = 131) 17.2 yo (12–25) 19.4 yo (12–24)
26-44 yo (n = 130) 37.4 yo (30–44) 38.2 yo (27–44)
>45 yo (n = 79) 58.5 yo (45–70) 59.6 yo (45–69)
Gender (Male:female ratio) 1.27 1.0
Mean Hba levels (g/dl) [±SD] 11.1 [±2.4] 11.4 [±1.1] 0.235
Hctb (%) [±SD] 32.4 [±3.5] 39.1 [±2.4] 0.045
Patient delay [PD] (days)/No. of patients (%) ≤3 d/204 (47%)
4–6 d/135 (31%)
≥7 d/95 (22%)
aHaemoglobin; bHaematocrit; p-values of <0.05 were deemed statistically significant.
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best fit the data across the whole cohort was
a parabola (a > 0, opening upwards; R2 = 0.43) sug-
gesting some age-related element to mEV release,
with plasma mEV levels decreasing between 0.5–25
yo patients and increasing in the 26–70 yo range.
Upon closer examination we found a negative corre-
lation in the age range 0.5–25 yo (Figure 2(b),
Pearson’s r = −0.587; p < 0.0001) and a positive
one in the 26–70 yo age range (Figure 2(c),
Pearson’s r = 0.668; p < 0.0001) The cohort, which
was restricted to those with parasitaemia levels of
51–500 parasites µL−1 (n = 141) was then divided
into four age groups (Figure 2(d)), ≤11 yo (n = 36),
12–25 yo (n = 42), 26–44 yo (n = 43) and ≥45 yo
(n = 20); neither gender nor haemoglobin levels
showed significant difference between the age
groups. We observed a “bimodal” age distribution
with respect to plasma mEV levels (Figure 2(d)).
Plasma mEV levels in children ≤11 yo were 1.43-
fold (143%) and 0.78-fold (78%) greater than for
12–25 yo and 26–44 yo, respectively, (both
p < 0.0001) and mEV levels in adults ≥45 yo were
1.21-fold (121%) and 0.63-fold (63%) greater than
for 12–25 yo and 26–44 yo, respectively, (both
p < 0.0001). In infected children under 11 yo (med-
ian plasma mEVs: 2.11 × 1010 mEVs µL−1) and
infected adults over 45 years of age (median plasma
mEVs: 1.92 × 1010 mEVs µL−1), mEV levels were
2.5-fold (250%) and 2.1-fold (210%) greater, than
their respective uninfected controls (Figure 2(d)).
However, in infected 12–25 yo (median
0.869 × 1010 plasma mEVs mL−1) and 26–44 yo
(median 1.189 × 1010 plasma mEVs mL−1), mEV
levels were only 1.1-fold (110%) and 1.8-fold
(180%) greater than respective uninfected controls.
These infected versus uninfected fold changes in
plasma mEVs, are summarized in Figure S2, essen-
tially confirming plasma mEV levels to be
significantly raised in infected compared to unin-
fected young children and the elderly. In view of
86% of victims of malaria arising globally in children
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Figure 1. Plasma mEVs in P. falciparum infected patients.
(a), Representative Nanosight Tracking Analysis (NTA) profile for isolated
mEVs from infected patients (12–44 yo). (b), Representative transmis-
sion electron microscope image for plasma mEVs isolated from a pool
of P. falciparum-infected patients, Bar 200 nm. (c), Western blot for
expression of typical markers of mEVs (β-tubulin) and sEVs (CD81) from
pooled infected samples carried out on mEV (15,000 × g) and sEV
(100,000 × g–15,000 × g) samples; the associated reversible zinc stain-
ing loading control is included. Forward (FSC PMT-A) and side scatter
(SSC-A) dot plots for mEVs isolated from infected patients (d) and
uninfected donors (e) and beneath, their corresponding dot plots for
AnV-FITC staining. (f), Box and Whisker plot showing median mEVs,
inter-quartile range and minimum-maximum from infected patients
(n = 434) and uninfected donors, counted by NTA. The mean values
are represented by a “+”.
Table 2. Patient delay, PD (time between first symptoms and
seeking medical attention [or period of acute illness]) and level
of parasitaemia measured.
Patient Delay
(Days/h)
No. of
patients
Parasite Density (No. of parasites µL−1)
20–50 51–500 501-8,000 8,001–40,000
“low” “low” “intermediate” “high”
1d/24 79 40 27 10 2
2d/48 60 21 26 8 5
3d/72 65 24 25 10 6
4d/96 50 12 18 12 8
5d/120 45 8 20 10 7
6d/144 40 3 12 19 6
7d/168 35 1 7 17 10
8d/192 30 0 3 12 15
≥9d/216 30 1 3 8 18
Total 434 110 141 106 77
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under the age of 5 [75], and 61% of suspected
malaria cases in Ghana being in the under-fives
[75], our finding, from a large sample size, is sig-
nificant. Interestingly, we also found a similar
though less distinct trend in the uninfected controls
(white box and whiskers plots, with filled data
points, in Figure 2(d)), mEV levels in ≥45 yo being
0.5-fold (50%) greater than both 26–44 yo
(p < 0.0001) and 12–25 yo (p < 0.0001) groups.
Similarly, mEV levels in ≤11 yo were 0.45-fold
(45%) greater than both 26–44 yo (p < 0.0001) and
12–25 yo (p < 0.0001) groups. There was no signifi-
cant difference between mEV levels of infected 12–25
yo and 26–44 yo (p = 0.125) or infected ≤11 yo and
≥45 yo (p = 0.504).
Parasite density which relates to plasma mEV
levels, is highest in the young and elderly
With relation to parasitaemia, we found plasma mEV levels
to have a hyperbolic relationship (R2 = 0.65) (Figure 3(a)),
andwhilst correlation analysis suggested that increased levels
of parasitaemia relate with increased mEV levels (Pearson’s
rank correlation, r = 0.587, p < 0.0001), the linear equation
did not fit as well as the rectangular hyperbola. This rise of
plasma mEV levels was also marked (r = 0.6) across a very
limited increase in parasitaemia at “low” parasite densities
(5–300 parasites μL−1) (Figure 3(a), inset). In view of the
association of parasitaemia and plasma mEV levels and the
“bimodal” age distribution of plasma mEV levels showing
peaks in the very young (≤11 yo) and elderly (≥45 yo) (Figure
a b
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Figure 2. Plasma mEV levels are significantly higher, at low parasitaemia levels, in infected young Ghanain children and the elderly.
(a), Scatter plot of number of mEVs and age of associated falciparum malaria infected patients (n = 141), (for patients with parasitaemia levels of
51–500 parasites µL−1). The data covering the age range 0.5–70 years was best fit by a parabola (graph of quadratic equation, showing 95%
confidence interval (CI) band; coefficient a > 0, opening upwards) but with no relationship between overall age and mEV levels for infected
patients. (b) Correlation analysis of plasma mEV levels and age, for age groups 0.5–25 yo (r = −0.587) and (c) 26–70 yo (r = 0.668). In (d), the same
data for plasma mEV levels ±CI from infected patients (n = 141) (all with parasitaemia levels of 51–500 parasites µL−1) is presented, but now also
including plasma mEV levels from uninfected donors (n = 133) for ≤11 yo, 12–25 yo, 26–44 yo and ≥45 yo, as box and whiskers plots, with the
median mEV levels (showing 95% CI) and mean represented by a “+”. Within each age group, mEV levels are compared between infected and
uninfected, p < 0.0001 (****).
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2(a,d)), we looked for any similar trendbetweenparasitaemia
and age. The relationship between log-transformed parasite
density and age allowed the fitting of a parabola, Figure 3(b),
(a > 0, opening upwards; R2 = 0.35), on a semi-log scale, but
with no linear relationship between parasitaemia and age
across the whole cohort (0.5–70 yo); r = −0.005, p = 0.95.
The parabolic relationship with peaks in parasitaemia in the
young and elderly, more clearly demonstrated in Figure 3(c)
andFigure S3, is likely due to these groupshaving lower levels
of immunity or defective immunity to malaria, which would
allow multiplication of the parasite (reflected in higher con-
comitant mEV levels). Looking at the raised levels of plasma
mEVs already at low parasitaemia levels (20–500 parasites
µL−1) it was not surprising that the percentage of infected
patients with mEVs above the median value (1.69 × 1010
mEVs mL−1), represented by the dotted red line in Figure 3
(a), was highest, especially at these low parasite levels,
amongst children and the elderly (Figure 3(d)). As part of
future work, it would be important to monitor possible
correlation between factors not considered, that may affect
plasmamEV levels, such as inflammatorymarkers. The stage
of parasite development (ring, trophozoite, schizont stage)
which might also affect mEV release however would only
affect mEVs released from erythrocytes [9].
mEV levels correlate with patient delay and are
raised early in infection
Since PD (in effect the period of acute illness) likely
indicates levels of parasitaemia (Figure S1), (which is
strongly related with plasma mEV levels (Figure 3(a)))
therefore PD was unsurprisingly found, in Figure 4(a),
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Figure 3. Hyperbolic relation between mEVs released and parasitaemia with significantly increased parasitaemia levels in the young
and elderly.
(a) Scatter plot of plasma mEVs and parasitaemia levels for the cohort (n = 175) recorded as having PD 2–4 days, with a rectangular hyperbolic
function fitted to the data. The dotted red and black lines represent, respectively, the median plasma mEV levels for infected and uninfected
samples in this study. A region of the same graph limited to mEV levels for corresponding parasite densities <300 parasites μL−1 is presented inset.
In (b), no correlation was found when parasitaemia was plotted against age (n = 175) for the same cohort on a semi-logarithmic plot, however the
data was best fit by a parabola (second order (quadratic) polynomial, coefficient a > 0, opening upwards). In (c), infected patients in age groups
<11 yo, 12–25 yo, 26–44 yo and ≥45 yo were compared for their recorded parasitaemia levels. In (d) the percentage of patients with mEVs above
the median level for infected patients in this study (1.69 × 1010 mL−1), is represented for three levels of parasitaemia, across the 4 age groups used
in this study.
8 S. ANTWI-BAFFOUR ET AL.
to be related with elevated plasma mEV levels
(r = 0.919, p < 0.0001, R2 = 0.847). Analysis of PD
and corresponding infected versus uninfected mEV
levels (Figure 4(b)) suggests that patients with low
parasitaemia early in infection already have higher
plasma mEV levels than healthy controls. This raises
the possibility of P. falciparum-specific markers in
mEVs being considered as future diagnostic targets.
At PD values of 3d, although 49/65 (75%) of patients
have low levels of parasitaemia (≤500 parasites µL−1),
mEV levels are already 0.93-fold (93%) greater than
that of uninfected controls (p = 0.046), whilst at
PD = 4d, with 30/50 (60%) of patients with low para-
sitaemia, mEV levels are 1.38-fold (138%) greater than
that of controls (p = 0.031). In view of the hyperbolic
relationship between parasitaemia and plasma mEV
levels, this is not unexpected, with initial small rises
in parasite density producing comparatively large
increases in mEV levels. With positive relationships
between mEV levels and parasitaemia (Figure 3(a))
and mEV levels and patient delay it was not surprising
that there would be some positive trend between para-
sitaemia and patient delay. Indeed, there was an expo-
nential growth in parasite density with patient delay
(Figure 4(c)). As shown inset in the semi-log plot, this
was linearized on a logarithmic axis, thus confirming
the exponential increase.
Gender had no influence on mEV levels (Figure 5)
in either infected or uninfected individuals (p = 0.667).
Of note, our previous study of plasma mEV levels in
healthy donors [64] (n = 57) also showed no effect of
gender (and only a slight, non-significant decrease with
age). This may be important to note as there are sig-
nificant biochemical and hormonal differences between
males and females that as far as we have so far
observed, do not impact on mEV release.
Discussion
Though previous studies have looked at correlations
between the severity of disease and plasma mEV levels,
the novelty of this cross-sectional field study is the
large number, n = 434, of patients analysed, allowing
for more secure conclusions, and also that plasma
mEVs were quantified by Nanosight Tracking
Analysis. One other study performed in Malawi also
showed increased levels of mEVs in children with
falciparum malaria aged 0.5–12 yo, although only
endothelial mEVs were quantified [48]. In another
study carried out by the same group, platelet mEVs
were most raised in cerebral malaria patients, but other
cell-specific mEVs at raised levels included those from
endothelial cells, leukocytes and erythrocytes [76]. Our
field study was not restricted to mEVs from any parti-
cular cell type, because a variety of different cells
including erythrocytes, leukocytes and platelets are
likely to generate mEVs following infection. This
increased release of mEVs could be through the action
of TNF-α [77], for example, which was shown to be
especially raised in cerebral malaria [78]. The mEVs
were confirmed by detection of mEV markers, electron
microscopy and NTA analysis. Exposed PS was also
observed; in vivo, exposed PS was found in mEVs from
iErys [40] and was thought to possibly be due to brief
exposure to febrile temperatures [41].
Our finding of significantly raised plasma mEV
levels in young children and the elderly suffering
from malaria, at low parasitaemia levels, is important
as it points to EVs acting as promising biomarkers
for falciparum malaria in these age groups. We also
found plasma mEV levels to be significantly raised in
patients at a PD of 3d, when the majority of patients
still have very low parasitaemia levels. Enumeration
of plasma mEVs from malaria-positive blood, by
NTA analysis, in early infection, could be developed
as an early diagnostic indicator. However, as
increased numbers are unlikely to be specific to
malaria infection, this could be coupled to the detec-
tion of parasite antigens in EVs, by fluorescence
NTA, for example. To reduce the numerous steps
required for purification by differential centrifuga-
tion, novel microfluidic systems which are being
developed [79], may be used. Besides detecting para-
site antigens in mEVs, EVs from infected erythro-
cytes carry Plasmodium RNAs [80] and
P. falciparum-specific lncRNAs [81,82], non-coding
RNAs being released in EVs from infected erythro-
cytes within 12 h [83], and therefore qRT-PCR could
be used to amplify Plasmodium-specific lncRNA in
EVs. This would provide a molecular diagnostic for
sub-microscopic (0.1–10 parasites μL−1) levels of
infection; a similar strategy for detecting
Schistosoma EV-derived miRNA was developed
recently [84]. This could become an invaluable tool
where there is a delay in seeking treatment, especially
in travellers returning to countries where malaria is
not endemic [7,50,85].
It should also be noted that in this study, any influ-
ence of background immunity and thus inflammatory
mediators which could also have affected plasma mEV
levels, was reduced as much as possible by the infec-
tious and autoimmune diseases included in the exclu-
sion criteria. Nevertheless, this study is now to be
followed by a more detailed longitudinal cohort
study, assessing an increased range of parameters,
beyond mEV levels, including inflammatory cytokines
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such as TNF-α, at the outset of infection, including in
low level malaria and through illness progression.
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Figure 4. Plasma mEV levels in infected patients are related
to patient delay and significantly raised early in infection.
In (a), plasma mEVs showed a positive correlation when plotted
against PD (Patient Delay or period of acute illness) for data collected
from patients (n = 141), at PD 1-9d (24–216 h) having a parasitaemia
of 51–500 parasites µL−1. In (b), number of patients (with the following
levels of parasitaemia: 20–50; 51–500; 501–8,000; 8,001–40,000 para-
sites µL−1) and mEVs were plotted against PD for the period 1-9d
(24–216 h). For clarity, 95% CI for mEV levels (line graphs) were not
displayed. (c) Parasite density (mean ±95%CI) plotted against patient
delay shows an exponential growth confirmed by the linearized semi-
log plot (inset).
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